BioSpace News Archive

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market opens on Tuesday, November 7, 2023.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock.

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2023 financial results will be reported on Monday, November 13, 2023, after the close of the financial markets.

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, announced it will host a virtual key opinion leader event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET.

Avalo Therapeutics, Inc., announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801, AVTX-802 and AVTX-803 to AUG Therapeutics, LLC.

Galera Therapeutics, Inc. announced that it has received official meeting minutes from the Type A meeting with the United States Food and Drug Administration held September 28, 2023 in which the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese for radiotherapy-induced SOM.

Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences in early November.

Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Verge Genomics announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.

OKYO Pharma Limited announced a $5.84M issuance of shares via: a Company managed registered direct offering of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share conducted without an underwriter or placement agent; and the extinguishment of payables of $4.20M by the issuance of 2,766,667 shares at the offering price of $1.50 per share.